Presentation Type
Poster
Location
Portland State University
Start Date
5-2-2018 11:00 AM
End Date
5-2-2018 1:00 PM
Subjects
Alzheimer Disease -- etiology, Amyloid beta-protein, Chelation therapy
Abstract
Alzheimer’s Disease (AD) is the sixth leading cause of death in the United States with no known methods to cure, reverse or halt disease progression. The “metal hypothesis” states that FeII, CuII, ZnII, and AlII bind to truncated Aβ peptides and form soluble oligomers which deposit as senile plaques. These plaques play a crucial role in AD pathogenesis. For example, metallated-Aβ aggregates are hypothesized to disrupt membranes or generate a reactive oxygen species (ROS) through redox cycling in the presence of CuI/II or FeIII/II and a reducing agent. ROS can lead to weakened synaptic signaling and neuronal cell death. In addition, the ratio of the metal:Aβ can form a variety of metallated-Aβ species which are both soluble and neurotoxic. Neurotoxicity can depend on the size of the metallated-Aβ species as well as the type of metal present. For example, some studies suggest that CuII ions inhibit aggregation and fibrillation reactions induced by ZnII ions and may therefore be neuroprotective in this scenario. Regardless to the contradicting roles of metals, the most convincing piece of evidence supporting a link between metal homeostasis and the two pathological processes (Aβ1-42 aggregation and oxidative damage) comes from chelation studies showing solubilization of Aβ deposits and clinical improvement of patients with AD. Studies suggest control of metal imbalances as well as Aβ concentrations are important “disease-modifying strategies”. Here we will present studies utilizing well-known metal ion capture agents, metallodithiolates or NiN2S2 ligands, as chelators to reverse Aβ aggregation. Fluorescence anisotropy, UV-Vis spectroscopy, and atomic force microscopy studies will show that interactions of Aβ with metal ions are reversible with metallodithiolate ligands. These studies will show that metallodithiolates might be a new class of ligands for reversing metal-induced Aβ aggregation and a potential disease modifying strategy.
Rights
© Copyright the author(s)
IN COPYRIGHT:
http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).
DISCLAIMER:
The purpose of this statement is to help the public understand how this Item may be used. When there is a (non-standard) License or contract that governs re-use of the associated Item, this statement only summarizes the effects of some of its terms. It is not a License, and should not be used to license your Work. To license your own Work, use a License offered at https://creativecommons.org/
Persistent Identifier
https://archives.pdx.edu/ds/psu/37988
Included in
Metallodithiolate Ligands for Reversing Metal Ion Induced Aggregation of Beta Amyloid
Portland State University
Alzheimer’s Disease (AD) is the sixth leading cause of death in the United States with no known methods to cure, reverse or halt disease progression. The “metal hypothesis” states that FeII, CuII, ZnII, and AlII bind to truncated Aβ peptides and form soluble oligomers which deposit as senile plaques. These plaques play a crucial role in AD pathogenesis. For example, metallated-Aβ aggregates are hypothesized to disrupt membranes or generate a reactive oxygen species (ROS) through redox cycling in the presence of CuI/II or FeIII/II and a reducing agent. ROS can lead to weakened synaptic signaling and neuronal cell death. In addition, the ratio of the metal:Aβ can form a variety of metallated-Aβ species which are both soluble and neurotoxic. Neurotoxicity can depend on the size of the metallated-Aβ species as well as the type of metal present. For example, some studies suggest that CuII ions inhibit aggregation and fibrillation reactions induced by ZnII ions and may therefore be neuroprotective in this scenario. Regardless to the contradicting roles of metals, the most convincing piece of evidence supporting a link between metal homeostasis and the two pathological processes (Aβ1-42 aggregation and oxidative damage) comes from chelation studies showing solubilization of Aβ deposits and clinical improvement of patients with AD. Studies suggest control of metal imbalances as well as Aβ concentrations are important “disease-modifying strategies”. Here we will present studies utilizing well-known metal ion capture agents, metallodithiolates or NiN2S2 ligands, as chelators to reverse Aβ aggregation. Fluorescence anisotropy, UV-Vis spectroscopy, and atomic force microscopy studies will show that interactions of Aβ with metal ions are reversible with metallodithiolate ligands. These studies will show that metallodithiolates might be a new class of ligands for reversing metal-induced Aβ aggregation and a potential disease modifying strategy.